EMBC Stock Analysis: Embecta | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 300m USD | 12M Return: -55.5% | US29082K1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.07M
EPS Trend: -22.8%
Qual. Beats: 1
Rev. Trend: -88.9%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 4.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Embecta Corp. (NASDAQ: EMBC) is a U.S.-based medical device company focused exclusively on diabetes care, offering pen needles, syringes, safety injection devices, and supporting digital applications for diabetes management. The company was spun off from Becton, Dickinson and Company (BD) in April 2022, inheriting BDs former Diabetes Care business, and is headquartered in Parsippany, New Jersey. Embecta primarily distributes its products through wholesalers and distributors, serving both the U.S. and international markets.
Operating within the GICS Health Care Supplies sub-industry, Embecta is positioned as a micro-cap player in the global diabetes care market, where demand is driven by the rising prevalence of diabetes and the ongoing shift toward injectable therapies such as insulin pens. Its business model is heavily dependent on third-party reimbursement, including government healthcare programs and private insurers, which is a defining characteristic of medical device suppliers in this sector.
- GLP-1 drug adoption pressures insulin injection demand
- Rising diabetes prevalence drives pen needle volume growth
- Wholesaler pricing power compresses product gross margins
| Net Income: 87.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 1.58 > 1.0 |
| NWC/Revenue: 28.01% < 20% (prev 36.83%; Δ -8.82% < -1%) |
| CFO/TA 0.14 > 3% & CFO 174.1m > Net Income 87.5m |
| Net Debt (1.32b) to EBITDA (273.7m): 4.82 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.5m) vs 12m ago 0.03% < -2% |
| Gross Margin: 59.89% > 18% (prev 63.01%; Δ -3.12% > 0.5%) |
| Asset Turnover: 84.10% > 50% (prev 95.26%; Δ -11.17% > 0%) |
| Interest Coverage Ratio: 2.29 > 6 (EBIT TTM 221.7m / Interest Expense TTM 96.7m) |
| A: 0.23 (Total Current Assets 705.1m - Total Current Liabilities 419.8m) / Total Assets 1.27b |
| B: -0.32 (Retained Earnings -404.3m / Total Assets 1.27b) |
| C: 0.18 (EBIT TTM 221.7m / Avg Total Assets 1.21b) |
| D: -0.33 (Book Value of Equity -612.7m / Total Liabilities 1.88b) |
| Altman-Z'' = 1.32 = BB |
| DSRI: 1.02 (Receivables 182.2m/192.9m, Revenue 1.02b/1.10b) |
| GMI: 1.05 (GM 63.01% / 59.89%) |
| AQI: 1.04 (AQ_t 0.19 / AQ_t-1 0.18) |
| SGI: 0.92 (Revenue 1.02b / 1.10b) |
| TATA: -0.07 (NI 87.5m - CFO 174.1m) / TA 1.27b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 5.90 with a total of 791,822 shares traded. Over the past week, the price has changed by +11.53%, over one month by +17.53%, over three months by +90.10% and over the past year by -55.48%.
Current recommended Stop Loss: 5.50 (which is 6.8% or 1.5 ATR below the current price).
Embecta has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold EMBC.
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 4 | -32.2% |
P/E Trailing = 3.5986
P/S = 0.2942
P/B = 2.6134
Revenue TTM = 1.02b USD
EBIT TTM = 221.7m USD
EBITDA TTM = 273.7m USD
Long Term Debt = 1.32b USD (from longTermDebt, last quarter)
Short Term Debt = 149.3m USD (from shortTermDebt, last quarter)
Debt = 1.53b USD (from shortLongTermDebtTotal, last quarter) + Leases 30.9m
Net Debt = 1.32b USD (calculated: Debt 1.53b - CCE 214.7m)
Enterprise Value = 1.62b USD (299.7m + Debt 1.53b - CCE 214.7m)
Interest Coverage Ratio = 2.29 (Ebit TTM 221.7m / Interest Expense TTM 96.7m)
EV/FCF = 9.83x (Enterprise Value 1.62b / FCF TTM 164.6m)
FCF Yield = 10.18% (FCF TTM 164.6m / Enterprise Value 1.62b)
FCF Margin = 16.16% (FCF TTM 164.6m / Revenue TTM 1.02b)
Net Margin = 8.59% (Net Income TTM 87.5m / Revenue TTM 1.02b)
Gross Margin = 59.89% ((Revenue TTM 1.02b - Cost of Revenue TTM 408.6m) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 56.45%)
Tobins Q-Ratio = 1.28 (Enterprise Value 1.62b / Total Assets 1.27b)
Interest Expense / Debt = 6.31% (Interest Expense 96.7m / Debt 1.53b)
Taxrate = 30.0% (37.5m / 125.0m)
NOPAT = 155.2m (EBIT 221.7m * (1 - 30.00%))
Current Ratio = 1.68 (Total Current Assets 705.1m / Total Current Liabilities 419.8m)
Debt / Equity = -2.50 (negative equity) (Debt 1.53b / totalStockholderEquity, last quarter -612.7m)
Debt / EBITDA = 4.82 (Net Debt 1.32b / EBITDA 273.7m)
Debt / FCF = 8.01 (Net Debt 1.32b / FCF TTM 164.6m)
Total Stockholder Equity = -625.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.22% (Net Income 87.5m / Total Assets 1.27b)
RoE = -13.98% (negative equity) (Net Income TTM 87.5m / Total Stockholder Equity -625.8m)
RoCE = 32.13% (EBIT 221.7m / Capital Employed (Equity -625.8m + L.T.Debt 1.32b))
RoIC = 16.44% (NOPAT 155.2m / Invested Capital 943.9m)
WACC = 4.73% (E(299.7m)/V(1.83b) * Re(6.33%) + D(1.53b)/V(1.83b) * Rd(6.31%) * (1-Tc(0.30)))
Discount Rate = 6.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.41 | Cagr: 0.54%
[DCF] Terminal Value 77.97% ; FCFF base≈151.7m ; Y1≈173.9m ; Y5≈255.9m
[DCF] Fair Price = 44.71 (EV 3.85b - Net Debt 1.32b = Equity 2.53b / Shares 56.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -22.81 | EPS CAGR: -2.76% | SUE: 1.93 | # QB: 1
Revenue Correlation: -88.89 | Revenue CAGR: -3.17% | SUE: 1.87 | # QB: 1
EPS current Quarter (2026-12-31): EPS=0.49 | Chg30d=+2.77% | Revisions=+25% | Analysts=3
EPS current Year (2026-09-30): EPS=1.83 | Chg30d=+14.92% | Revisions=+50% | GrowthEPS=-37.8% | GrowthRev=-5.1%
EPS next Year (2027-09-30): EPS=1.76 | Chg30d=+1.29% | Revisions=+50% | GrowthEPS=-4.0% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +70% (up=7, down=0)